Head-to-head evidence
MP-513 vs SYR-472
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: DPP-4 · full Type 2 Diabetes pipeline
MP-513
Developed by Mitsubishi Tanabe Pharma
NCT00974090 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo-controlled Phase 3 study of 194 adults with type 2 diabetes inadequately controlled on sulfonylurea therapy, with a 12-week double-blind period followed by a 40-week open-label extension. The primary endpoint - change from baseline in HbA1c at Week 12 - is a hard, regulator-accepted measure of glycemic control, and the comparison clearly favored teneligliptin (LS mean -0.71% vs +0.29% for placebo, SE 0.06 per arm), however statistical significance is not reported.
SYR-472
Developed by Takeda Pharmaceutical Company
NCT02324569 · Phase 3 · completed
The 12-week comparison randomized 240 participants and used quadruple blinding with placebo control. The primary HbA1c endpoint was met, with a statistically significant treatment difference, but HbA1c is a surrogate laboratory measure rather than a hard clinical endpoint; the subsequent long-term period was open-label.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: MP-513's landscape · SYR-472's landscape